Annual Report

Overview

The report describes Relief's 2020 focus on advancing RLF-100 (aviptadil) for COVID-19 respiratory indications, including FDA Fast Track and Expanded Access designations. It highlights CHF 58 million in new equity financing and a strengthened management team with new medical, financial and commercial leadership. The consolidated statements report CHF 43.1 million in cash at December 31, 2020 and a CHF 7.8 million net loss.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2020
Period: Ends 31 December 2020
Publication date: 15 April 2021
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services